[Refractory asthma: underlying mechanisms, diagnosis and new therapeutic approach].
There has been a recent increase in the prevalence of asthma worldwide. Most cases can be satisfactorily managed with a combination of inhaled corticoids and bronchodilators. However, some 10% of patients remain symptomatic despite high doses of inhaled corticosteroids and long-acting beta-2 agonists. They represent a heterogeneous group consisting of those who are either undertreated, or really refractory to current available treatment.
Manise
M
M
CHU Sart Tilman, Liège.
Louis
R
R
D058666:Adrenergic beta-2 Receptor Agonists; D000318:Adrenergic beta-Agonists / Q000494:pharmacology / Q000627:therapeutic use; D001249:Asthma / Q000175:diagnosis / Q000188:drug therapy* / Q000453:epidemiology; D001993:Bronchodilator Agents / Q000494:pharmacology / Q000627:therapeutic use; D004351:Drug Resistance; D005938:Glucocorticoids / Q000494:pharmacology / Q000627:therapeutic use; D006801:Humans; D012720:Severity of Illness Index
D058666:Adrenergic beta-2 Receptor Agonists; D000318:Adrenergic beta-Agonists; D001993:Bronchodilator Agents; D005938:Glucocorticoids